Market Cap 592.57M
Revenue (ttm) 18.14M
Net Income (ttm) -72.85M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 649,900
Avg Vol 936,122
Day's Range N/A - N/A
Shares Out 188.72M
Stochastic %K 2%
Beta 1.98
Analysts Strong Sell
Price Target $4.50

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reaw...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 469 0914
Address:
701 Veterans Circle, Warminster, United States
CapitalismUSA
CapitalismUSA Aug. 19 at 12:28 PM
$ABUS $MRNA Royalties on Moderna’s cancer vaccine? Or will they just infringe/steal the LNP patent again?
0 · Reply
DocPharm
DocPharm Aug. 19 at 12:28 PM
$ABUS this is correct ✅
1 · Reply
Beach27
Beach27 Aug. 19 at 12:22 PM
$ABUS Gemini says Moderna is using our delivery system, cancer was not given away. They can use it for free, until approval. Then they need to talk to ROIV and ABUS
1 · Reply
Thalassophile
Thalassophile Aug. 19 at 12:20 PM
0 · Reply
NakdEnergy
NakdEnergy Aug. 19 at 12:11 PM
$ABUS anyone here feeling ripped off?
1 · Reply
RyanCalvin83
RyanCalvin83 Aug. 19 at 12:00 PM
$ABUS the settlement with Moderna only covered infectious disease I think. Be interesting to see what mRNA Moderna are using for the cancer treatment
3 · Reply
DaxCo
DaxCo Aug. 19 at 11:21 AM
$ABUS #biontech , settle now or never........ look at #Moderna mrna cancer vaccine looking good. But you have to settle with us first.
1 · Reply
NakdEnergy
NakdEnergy Aug. 19 at 11:13 AM
$ABUS how’s $MRNA delivering their cancer vaccine? Did we give that away also?
1 · Reply
Blueviking
Blueviking Aug. 19 at 10:33 AM
$ABUS Whats up with the 13% dip. Little manipulation here i should say😖😖😖
1 · Reply
banff
banff Aug. 19 at 9:36 AM
$ABUS premarket ?
2 · Reply
Latest News on ABUS
Arbutus Biopharma Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 7 days ago

Arbutus Biopharma Quarterly report: Q2 2026


Arbutus Biopharma Earnings release: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 7 days ago

Arbutus Biopharma Earnings release: Q2 2026


Arbutus Biopharma Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Arbutus Biopharma Quarterly report: Q1 2026


Arbutus Biopharma Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Arbutus Biopharma Earnings release: Q1 2026


Arbutus Biopharma granted Fast Track designation for imdusiran

2026-04-15T11:35:22.000Z - 4 months ago

Arbutus Biopharma granted Fast Track designation for imdusiran


Arbutus Biopharma Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Arbutus Biopharma Proxy statement: Proxy filing


Arbutus Biopharma Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 4 months ago

Arbutus Biopharma Proxy statement: Proxy filing


Arbutus Biopharma Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Arbutus Biopharma Earnings release: Q4 2025


Arbutus Biopharma Annual report: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Arbutus Biopharma Annual report: Q4 2025


Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?

2026-03-04T16:55:47.000Z - 5 months ago

Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?

MRNA


Arbutus Biopharma Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Arbutus Biopharma Earnings release: Q3 2025


Arbutus Biopharma Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Arbutus Biopharma Quarterly report: Q3 2025


Arbutus Biopharma Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q2 2025


Arbutus Biopharma Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Arbutus Biopharma Quarterly report: Q2 2025


Arbutus Biopharma Quarterly report: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Quarterly report: Q1 2025


Arbutus Biopharma Earnings release: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q1 2025


Arbutus Biopharma Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Arbutus Biopharma Proxy statement: Proxy Filing


Arbutus Biopharma Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Arbutus Biopharma Proxy statement: Proxy Filing


Arbutus Biopharma Earnings release: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q4 2024


Arbutus Biopharma Annual report: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Annual report: Q4 2024


Arbutus Provides 2025 Corporate and Financial Update

Jan 13, 2025, 7:30 AM EST - 1 year ago

Arbutus Provides 2025 Corporate and Financial Update


Arbutus Biopharma Transcript: Status Update

Dec 3, 2024, 11:00 AM EST - 1 year ago

Arbutus Biopharma Transcript: Status Update


Arbutus to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference


Arbutus Biopharma Earnings Call Transcript: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Earnings Call Transcript: Q3 2024


Arbutus Biopharma Quarterly report: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Quarterly report: Q3 2024


Arbutus Biopharma Earnings release: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Earnings release: Q3 2024


Arbutus to Participate in Two Upcoming Investor Conferences

Sep 3, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Participate in Two Upcoming Investor Conferences


Arbutus Biopharma Earnings Call Transcript: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q2 2024


Arbutus Biopharma Quarterly report: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Quarterly report: Q2 2024


Arbutus Biopharma Earnings release: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings release: Q2 2024


Arbutus Distributors Ltd. News Release

Jun 3, 2024, 9:50 AM EDT - 2 years ago

Arbutus Distributors Ltd. News Release


Arbutus to Present Imdusiran Data at EASL Congress 2024

May 22, 2024, 2:00 AM EDT - 2 years ago

Arbutus to Present Imdusiran Data at EASL Congress 2024


Arbutus Biopharma Earnings Call Transcript: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q1 2024


Arbutus Biopharma Quarterly report: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Quarterly report: Q1 2024


Arbutus Biopharma Earnings release: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings release: Q1 2024


Arbutus Biopharma Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Arbutus Biopharma Proxy statement: Proxy Filing


Arbutus Biopharma Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Arbutus Biopharma Proxy statement: Proxy Filing


Arbutus Biopharma Earnings Call Transcript: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q4 2023


Arbutus Biopharma Annual report: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Annual report: Q4 2023


Arbutus Biopharma Earnings release: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings release: Q4 2023


Arbutus Biopharma Slides: Corporate Presentation

Nov 9, 2023, 7:00 AM EST - 3 years ago

Arbutus Biopharma Slides: Corporate Presentation


Arbutus Biopharma Earnings Call Transcript: Q3 2023

Nov 7, 2023, 8:45 AM EST - 3 years ago

Arbutus Biopharma Earnings Call Transcript: Q3 2023


Arbutus Biopharma Quarterly report: Q3 2023

Nov 7, 2023, 8:45 AM EST - 3 years ago

Arbutus Biopharma Quarterly report: Q3 2023


Arbutus Biopharma Earnings release: Q3 2023

Nov 7, 2023, 8:45 AM EST - 3 years ago

Arbutus Biopharma Earnings release: Q3 2023


CapitalismUSA
CapitalismUSA Aug. 19 at 12:28 PM
$ABUS $MRNA Royalties on Moderna’s cancer vaccine? Or will they just infringe/steal the LNP patent again?
0 · Reply
DocPharm
DocPharm Aug. 19 at 12:28 PM
$ABUS this is correct ✅
1 · Reply
Beach27
Beach27 Aug. 19 at 12:22 PM
$ABUS Gemini says Moderna is using our delivery system, cancer was not given away. They can use it for free, until approval. Then they need to talk to ROIV and ABUS
1 · Reply
Thalassophile
Thalassophile Aug. 19 at 12:20 PM
0 · Reply
NakdEnergy
NakdEnergy Aug. 19 at 12:11 PM
$ABUS anyone here feeling ripped off?
1 · Reply
RyanCalvin83
RyanCalvin83 Aug. 19 at 12:00 PM
$ABUS the settlement with Moderna only covered infectious disease I think. Be interesting to see what mRNA Moderna are using for the cancer treatment
3 · Reply
DaxCo
DaxCo Aug. 19 at 11:21 AM
$ABUS #biontech , settle now or never........ look at #Moderna mrna cancer vaccine looking good. But you have to settle with us first.
1 · Reply
NakdEnergy
NakdEnergy Aug. 19 at 11:13 AM
$ABUS how’s $MRNA delivering their cancer vaccine? Did we give that away also?
1 · Reply
Blueviking
Blueviking Aug. 19 at 10:33 AM
$ABUS Whats up with the 13% dip. Little manipulation here i should say😖😖😖
1 · Reply
banff
banff Aug. 19 at 9:36 AM
$ABUS premarket ?
2 · Reply
hopeful2bright
hopeful2bright Aug. 19 at 3:11 AM
$ABUS I truly expect something big will happen within the next year or so. Everyone’s situation is different but started the rally today at bottom picking up another 50k shares. WILL NOT buy anymore and if she goes down interim, doesn’t matter to me. Here for ABUS HepB and PFE settlement. IMO, over $10 this year. Better than 3.6% I’m getting on cash over next year.
0 · Reply
Joe_Mama
Joe_Mama Aug. 18 at 10:00 PM
$ABUS I’ve filled in the visual aide Bring on $5.33
2 · Reply
StockosaurusTex
StockosaurusTex Aug. 18 at 8:30 PM
$ABUS "special dividend.. no special dividend.. sell to Roviant... not sell to roviant... get hosed in Moderna settlement... right on that sir."
1 · Reply
FatedFish
FatedFish Aug. 18 at 7:59 PM
$ABUS Big volume day today!!!! Wow
0 · Reply
Blueviking
Blueviking Aug. 18 at 7:57 PM
$ABUS No wayyy
1 · Reply
Nile1
Nile1 Aug. 18 at 7:45 PM
$ABUS the upper end of the forecast range for today’s close, August 18, is $4.91. We’re still within the range. Wow.
0 · Reply
Joe_Mama
Joe_Mama Aug. 18 at 6:33 PM
$ABUS Target $4.83 and then $5.33 soon after. Call it circle ⭕️ theory
2 · Reply
LM_Johanssen
LM_Johanssen Aug. 18 at 6:25 PM
1 · Reply
FatedFish
FatedFish Aug. 18 at 6:13 PM
$ABUS At least it's holding above 4.50 for a while now. I want news though. Wtf are they doing with HBV and the Imdurisan and PD-L1 AB101??? And buyout or settlement from Pfizer or do we have to wait until spring 2027 like what happened with moderna? What about the Genevant money? Dividend? Share buyback? I'm about done with this stock lol want to cash out but not until the writing is on the wall and the price reflects actual value. I'm up, but it could be better lol
2 · Reply
Wonderbread1988
Wonderbread1988 Aug. 18 at 1:57 PM
$ABUS dating back to 10/11/18 there has been a massive sell wall/short/resistance at and above 4.7ish. More recently we’ve been knocking pretty hard but the market doesn’t seem to value us at a higher pps just yet
2 · Reply
StockosaurusTex
StockosaurusTex Aug. 18 at 1:40 PM
$ABUS "investor relations this is Walter, how can I assist you today?"
2 · Reply
Planetpaprika
Planetpaprika Aug. 18 at 11:38 AM
$ABUS https://www.law360.com/articles/2514311/moderna-arbutus-clash-on-gov-t-venue-for-vax-ip-claims Based on the current record I would regard Arbutus as having the stronger position on the core §1498 issue...Delaware district court already rejected most of M’s §1498 defense. M is now appealing that specific issue to the Fed Circuit. ...Judge Wolson's February 2, 2026 decision was quite damaging to M. He found that the overwhelming majority of the doses went to the general public,not to the Government itself. Gov paid for them,but payment isn't necessarily the same thing as the patented invention being used “for the Government": He specifically relied on the older Larson principle: medical treatment is provided for the patient,rather than for the government merely because the Gov funds it. That's the heart of ABUS's argument. DC essentially split the vaccines into 2 categories: 1. Vaccines distributed to the general public → §1498 does not shield M. 2. Vaccines the Gov acquired+distributed directly to its own employees → §1498 does apply to direct infringement.
1 · Reply